Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE"

Transcription

1 Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

2 CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours: It was already happening and demand was predicted to increase Funding was not well established and therefore access is variable across the UK Published data from quality assurance schemes suggested that there were issues with the reproducibility and accuracy of results Further work was needed in formalin-fixed, paraffin embedded tissue for large-scale routine NHS testing There was no clear consensus on who to test, how to test, what to test or how to report results

3 Probability of progression Free Survival Proportion Progression-Free Probability of progression Free Survival Stratified Medicine Targeted treatment no more effective than placebo overall Targeted treatment more effective than standard treatment if mutation is present Targeted Treatment Placebo Standard Treatment Targeted Treatment Time to progression (months) Months since randomisation Unstratified Population Stratified Population Targeted treatment less effective than standard treatment if mutation is not present Standard Treatment Targeted Treatment Is the NHS ready for new targeted therapies? Graphs adapted from Giaccone, G. et al. J Clin Oncol; 22: , Mok T et al. N Engl J Med 2009;361: Months since randomisation

4 Information Systems for Stratified Medicine The ultimate solutions were to be able to link to existing data sources with clear explanation and demonstration of how they would be useful in cancer science and medicine, including: retrieval and integration of diverse NHS datasets concerning cancer patients e.g. national minimum datasets, genetic data and patient records maintenance of a secure database where the individual s right to privacy is demonstrably protected allocation of controlled access to validated members of the research community scalability any solution will need to be scalable to ultimately incorporate millions of patient records, including varied clinical data with the expected massive scale of stratification data (molecular or imaging) and formats (images, defined datasets, free text)

5 Stratified Medicine Programme Cancer Patients Central Repository DB Compiled Clinical Data Extract Clinical Hubs Leeds Man Edin Glas Camb Card XML Genetic Results Anonymised Data Researchers Partners NHS RMH Sample + XML Test Request Birm Business Processes / Interoperability standards Delivery Research Cardiff Birm ICR Genetic Technology Hubs

6 Dataset for Stratified Medicine Patient Demographic (name, address, age, gender, ethnicity) from Stratified Medicine Dataset Referral (date, main specialty, organisation) - from Stratified Medicine Dataset Consultation (date, primary diagnosis, basis and grade) - from Stratified Medicine Dataset Co-morbidities Consent Cancer Care Plan From MDT (SM Dataset) Pathology (date, pathological staging (TNM), differentiation, MDx (including gene, scope, method, mutations), histology, margin, invasion) Imaging (integrated staging (TNM) DNA (source, amount banked)- from SM Dataset Treatment Surgery (date, procedure, site) Treatment Chemotherapy Treatment Radiotherapy (date, intent, regimen, changes) (date, intent, site) Outcome Death (date, cause, ID) From ONS Dataset and local death reporting Outcome PFS (date, continuous updates, follow up ) + additional information From Chemotherapy Dataset Outcome Relapse (A&E, Outpatient and Inpatient activity which can be used an indication of relapse) From HES

7 Analysis and Reporting Collation of all data extracts in central repository - Cambridge Installation of research database and Cohort Explorer - Oxford Export of Stratified Medicine cohort (approx 9000 anonymised patient records clinical, pathology and genomic data) Requirements for both fixed reports and ad hoc analysis; user licences for clinical and technology hubs Community of knowledge to explore the potential further using data export Developmental use for further analysis and proof of concept for Next Generation Sequencing (NGS) molecular diagnostics

8 Oracle Enterprise Healthcare Analytics TRC Platform EHA App Exchange Biobanks Cohort Explorer Oracle Analytic Apps Exec Clinical Systems Financial Systems Administrative Systems Oracle Healthcare Analytics Data Integration Omics Loaders Term. Service Healthcare Data Model Omics Data Bank Unit of MPI NLP Measure Master Data Management & Other Services De identification Partner Apps Custom Apps Operating Room Analytics Provider Supply Chain Analytics Registries Quality Reporting Rev Cycle Administrator Clinician Staff Research Systems Oracle Data Integrator INFA Oracle Database Pharma covigilance Researcher Data Integration Enterprise Data Warehouse / Data Model Analytics & Reporting

9 Challenges Remaining Embedding molecular diagnostic testing for multiple markers into patient pathways Achieving clinically relevant turnaround times Moving towards a single panel approach Establishing standards for molecular pathology Establishing routine consent of patients and samples for research Sufficient resources and clinical support to enable delivery of clinical data for research Capability to extract follow up and broader outcomes data

10

11 Applications of the Clinical Data Describing the characteristics of the patient cohorts Prevalence of molecular abnormalities in the UK population and comparison to other published data Range of mutations seen and other findings e.g. amplification/deletion of genes involved in rearrangements Co-existence of mutations in individual tumours Clinical correlates of mutation-positive cases e.g. morphology, stage of disease, survival Identifying patients who may be eligible for entry to stratified clinical trials Informing sample size calculations for future studies in subgroups with rare mutations

12 The Impact on Patients A service delivery model has now been established for molecular diagnostics in the UK The structured interoperability of the systems (using XML messaging) has been key to success and strongly endorsed by clinicians at the hospitals and labs Patients tests and results are happening much more quickly and effectively than before The accuracy and consistency of reporting these results improves patient safety and access to treatment Cohort exploration and analysis is increasing our knowledge and expertise which in turn leads to improving diagnosis, treatment and outcomes

13 Acknowledgements The patients who consented to take part in the Programme Investigators and teams at the clinical and technology hubs, and their NHS colleagues Stratified Medicine Programme staff at CRUK HQ National Cancer Registration Service University of Oxford and OHIS Funding partners AstraZeneca and Pfizer Other partners; Oracle, EMC 2, Roche, BMS

14 Monica Jones MBCS CITP Enterprise Architect QUESTIONS?

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons

More information

The Future of Personalized Medicine: Powered by Real World Data. Kris Joshi, PhD Global Vice President

The Future of Personalized Medicine: Powered by Real World Data. Kris Joshi, PhD Global Vice President The Future of Personalized Medicine: Powered by Real World Data Kris Joshi, PhD Global Vice President Safe Harbor Statement The following is intended to outline our general product direction. It is intended

More information

The 100,000 genomes project

The 100,000 genomes project The 100,000 genomes project Tim Hubbard @timjph Genomics England King s College London, King s Health Partners Wellcome Trust Sanger Institute ClinGen / Decipher Washington DC, 26 th May 2015 The 100,000

More information

SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime

SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime Stephan Schindewolf, SAP SE, July 13, 2015 Facts per Decision Need Decision

More information

Clinical Research Infrastructure

Clinical Research Infrastructure Clinical Research Infrastructure Enhancing UK s Clinical Research Capabilities & Technologies At least 150m to establish /develop cutting-edge technological infrastructure, UK wide. to bring into practice

More information

Personalized Medicine: Humanity s Ultimate Big Data Challenge. Rob Fassett, MD Chief Medical Informatics Officer Oracle Health Sciences

Personalized Medicine: Humanity s Ultimate Big Data Challenge. Rob Fassett, MD Chief Medical Informatics Officer Oracle Health Sciences Personalized Medicine: Humanity s Ultimate Big Data Challenge Rob Fassett, MD Chief Medical Informatics Officer Oracle Health Sciences 2012 Oracle Corporation Proprietary and Confidential 2 3 Humanity

More information

Information for patients and the public and patient information about DNA / Biobanking across Europe

Information for patients and the public and patient information about DNA / Biobanking across Europe Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes

More information

Blood Cancers Data Quality Report

Blood Cancers Data Quality Report Blood Cancers Data Quality Report National Cancer Data Repository (NCDR) - 21 Haematological Malignancies Site-Specific Clinical Reference Group Knowledge and Intelligence Team (Northern and Yorkshire)

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

BioGrid s use of Business Analytics for Collaborative Medical Research. Maureen Turner, CEO, BioGrid Australia

BioGrid s use of Business Analytics for Collaborative Medical Research. Maureen Turner, CEO, BioGrid Australia BioGrid s use of Business Analytics for Collaborative Medical Research Maureen Turner, CEO, BioGrid Australia Overview Data sharing considerations BioGrid a collaborative model Data ethics, privacy, security

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)

More information

Informatics: Opportunities & Applications. Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit

Informatics: Opportunities & Applications. Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit Informatics: Opportunities & Applications Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit Routine Data "routine data" is data collected as byproducts of clinical

More information

Haematological cancers: improving outcomes

Haematological cancers: improving outcomes Haematological cancers: improving outcomes Consultation on draft scope Stakeholder comments table 14/04/15 to 30/04/15 ID Stakeholder Page 3 Roche General General Specific consideration should be given

More information

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010 Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices Response from Cancer Research UK to the Commission August 2010 1. Cancer Research UK (CR-UK) 1 is leading the world in finding

More information

The 100,000 Genomes Project The North East and North Cumbria Genomic Medicine Centre

The 100,000 Genomes Project The North East and North Cumbria Genomic Medicine Centre The 100,000 Genomes Project The North East and North Cumbria Genomic Medicine Centre Rare Disease Recruitment Gastroenterological disorders Introduction & Eligibility Pack Invitation Pack Printed: 16/09/2016

More information

ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS

ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS INCORPORATE GENOMIC DATA INTO CLINICAL R&D KEY BENEFITS Enable more targeted, biomarker-driven clinical trials Improves efficiencies, compressing

More information

Treatment Routes in Prostate Cancer Urological Cancers SSCRG

Treatment Routes in Prostate Cancer Urological Cancers SSCRG 1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.

More information

Analysis of Population Cancer Risk Factors in National Information System SVOD

Analysis of Population Cancer Risk Factors in National Information System SVOD Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires

More information

Worldwide Collaborations in Molecular Profiling

Worldwide Collaborations in Molecular Profiling Worldwide Collaborations in Molecular Profiling Lillian L. Siu, MD Director, Phase I Program and Cancer Genomics Program Princess Margaret Cancer Centre Lillian Siu, MD Contracted Research: Novartis, Pfizer,

More information

EHR4CR ENABLING PROACTIVE RESEARCH

EHR4CR ENABLING PROACTIVE RESEARCH EHR4CR ENABLING PROACTIVE RESEARCH Neelam Patel Neelam Consulting Electronic Health Records for Clinical Research 76 Why change how I currently operate? To more visible to the clinical trial community

More information

Translational research facilitating experimental medicine in dementia in the UK

Translational research facilitating experimental medicine in dementia in the UK Translational research facilitating experimental medicine in dementia in the UK Simon Lovestone Director Biomedical Research Unit for dementia at Maudsley and King s Route Map for Dementia Research June

More information

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September

More information

National Bowel Cancer Audit Report 2008 Public and Executive Summary

National Bowel Cancer Audit Report 2008 Public and Executive Summary National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland

More information

Medical research charities and the NHS - how can we get the best for patients?

Medical research charities and the NHS - how can we get the best for patients? Medical research charities and the NHS - how can we get the best for patients? Dr Liz Philpots, head of research 2015 Annual NHS R&D forum 5-6 May 2015 overview getting the best for patients scene setting

More information

Connecting Basic Research and Healthcare Big Data

Connecting Basic Research and Healthcare Big Data Elsevier Health Analytics WHS 2015 Big Data in Health Connecting Basic Research and Healthcare Big Data Olaf Lodbrok Managing Director Elsevier Health Analytics o.lodbrok@elsevier.com t +49 89 5383 600

More information

<Insert Picture Here> The Evolution Of Clinical Data Warehousing

<Insert Picture Here> The Evolution Of Clinical Data Warehousing The Evolution Of Clinical Data Warehousing Srinivas Karri Principal Consultant Agenda Value of Clinical Data Clinical Data warehousing & The Big Data Challenge

More information

Technology Assisting Cancer Outcomes: Automated Biomarker Abstraction Overcoming Textual Data-Silos

Technology Assisting Cancer Outcomes: Automated Biomarker Abstraction Overcoming Textual Data-Silos Technology Assisting Cancer Outcomes: Automated Biomarker Abstraction Overcoming Textual Data-Silos Patrick Mergler, MBA PMP CPHIMS DISCLAIMER: The views and opinions expressed in this presentation are

More information

IBCSG Tissue Bank Policy

IBCSG Tissue Bank Policy THE INTERNATIONAL BREAST CANCER STUDY GROUP IBCSG Tissue Bank Policy Accepted by the IBCSG Executive Committee on March 24, 2006 Accepted by the IBCSG Ethics Committee on March 24, 2006 Accepted by the

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

The third all breast cancer report

The third all breast cancer report The third all breast cancer report Back to basics: Breast cancer incidence and mortality West Midlands Knowledge and Intelligence Team, Public Health England and the National Cancer Intelligence Network

More information

Big Data for Population Health

Big Data for Population Health Big Data for Population Health Prof Martin Landray Nuffield Department of Population Health Deputy Director, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery University of Oxford

More information

Measuring quality along care pathways

Measuring quality along care pathways Measuring quality along care pathways Sarah Jonas, Clinical Fellow, The King s Fund Veena Raleigh, Senior Fellow, The King s Fund Catherine Foot, Senior Fellow, The King s Fund James Mountford, Director

More information

The Molecular Diagnostic Market and development of personalized molecular tests

The Molecular Diagnostic Market and development of personalized molecular tests The Molecular Diagnostic Market and development of personalized molecular tests Dr. Iris Simon Sr. Director Research & Development, Agendia NV, Amsterdam NL and Irvine CA Agendia - Who are we Molecular

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Data Quality: Review of Arrangements at the Velindre Cancer Centre Velindre NHS Trust

Data Quality: Review of Arrangements at the Velindre Cancer Centre Velindre NHS Trust Data Quality: Review of Arrangements at the Velindre Cancer Centre Velindre NHS Audit year: 2010-11 Issued: August 2012 Document reference: 358A2012 Status of report This document has been prepared for

More information

UK Biobank. Integrating electronic health records into the UK Biobank Resource. Version 1.0. http://www.ukbiobank.ac.

UK Biobank. Integrating electronic health records into the UK Biobank Resource. Version 1.0. http://www.ukbiobank.ac. UK Biobank Integrating electronic health records into the UK Biobank Resource Version 1.0 http://www.ukbiobank.ac.uk/ January 2014 This document provides details on the procedures involved in processing

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Innovation Platform: Sudden Cardiac Death

Innovation Platform: Sudden Cardiac Death Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration

More information

Consent for Systemic Anti Cancer Therapy (SACT)

Consent for Systemic Anti Cancer Therapy (SACT) Consent for Systemic Anti Cancer Therapy (SACT) Guidance issued by the National Chemotherapy Board May 2016 Supported by: Contents National Chemotherapy Board 1. Introduction 1.1. Purpose of the guidance

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

Next Generation Information Management Systems for Research, Development and Decision Support

Next Generation Information Management Systems for Research, Development and Decision Support Next Generation Information Management Systems for Research, Development and Decision Support Dr. Werner Eberhardt, SAP AG Paris July 11, 2013 Matthias Steinbrecher, ICP, Berlin Dr. Matthieu-P. Schapranow,

More information

School of Nursing. Presented by Yvette Conley, PhD

School of Nursing. Presented by Yvette Conley, PhD Presented by Yvette Conley, PhD What we will cover during this webcast: Briefly discuss the approaches introduced in the paper: Genome Sequencing Genome Wide Association Studies Epigenomics Gene Expression

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014 The Stock Market Show Parsortix non-invasive cancer diagnostics Andrew Newland 13 September 2014 Legal disclaimer The information and opinions contained in this presentation are provided as at the date

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE CENTRE FOR HEALTH TECHNOLOGY EVALUATION. Technology Appraisals Programme

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE CENTRE FOR HEALTH TECHNOLOGY EVALUATION. Technology Appraisals Programme Page 1 of 14 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE CENTRE FOR HEALTH TECHNOLOGY EVALUATION Technology Appraisals Programme Specification for Cancer Drugs Fund data collection arrangements 1

More information

Biomarkers and Treatments Designing Trials. Mahesh KB Parmar MRC Clinical Trials Unit London. (based on a presentation given by Janet Dancey, US NCI)

Biomarkers and Treatments Designing Trials. Mahesh KB Parmar MRC Clinical Trials Unit London. (based on a presentation given by Janet Dancey, US NCI) Biomarkers and Treatments Designing Trials Mahesh KB Parmar MRC Clinical Trials Unit London (based on a presentation given by Janet Dancey, US NCI) Oncology Therapeutics Development Risk/benefit: Since

More information

Find the signal in the noise

Find the signal in the noise Find the signal in the noise Electronic Health Records: The challenge The adoption of Electronic Health Records (EHRs) in the USA is rapidly increasing, due to the Health Information Technology and Clinical

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Using the Grid for the interactive workflow management in biomedicine. Andrea Schenone BIOLAB DIST University of Genova

Using the Grid for the interactive workflow management in biomedicine. Andrea Schenone BIOLAB DIST University of Genova Using the Grid for the interactive workflow management in biomedicine Andrea Schenone BIOLAB DIST University of Genova overview background requirements solution case study results background A multilevel

More information

CLINICAL GOVERNANCE POLICY

CLINICAL GOVERNANCE POLICY Clinical governance is defined as: CLINICAL GOVERNANCE POLICY A framework through which NHS organisations are accountable for continually improving the quality of their services and safeguarding high standards

More information

General. Identification

General. Identification SIGNAL - Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing

More information

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Dr. Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate F Health DG Research and European Commission iiro.eerola@ec.europa.eu

More information

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic nonsmall-cell

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic nonsmall-cell Diagnostics Assessment Report (DAR) - s reference RR1. 1. All All Any test used to detect EGFR status should be fully validated. Laboratories providing a diagnostic service should participate in external

More information

Perspectives for Effective Cancer Drug Development The EORTC SPECTA program (Screening Patients for Efficient Clinical Trial Access)

Perspectives for Effective Cancer Drug Development The EORTC SPECTA program (Screening Patients for Efficient Clinical Trial Access) Perspectives for Effective Cancer Drug Development The EORTC SPECTA program (Screening Patients for Efficient Clinical Trial Access) Denis Lacombe Director EORTC HQ, Brussels, Belgium WIN 2014 Contents

More information

Merseyside & Cheshire Cancer Network Dashboard

Merseyside & Cheshire Cancer Network Dashboard Merseyside & Cheshire Cancer Network Dashboard May 2010. If you wish to know more about the Cancer Network Dashboard please contact the Merseyside and Cheshire Cancer Network. Version2.0 Part 2 Cancer

More information

Lung Cancer Consultant Outcomes Publication

Lung Cancer Consultant Outcomes Publication Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

More information

Guide to Ensuring Data Quality in Clinical Audits

Guide to Ensuring Data Quality in Clinical Audits Guide to Ensuring Data Quality in Clinical Audits Nancy Dixon and Mary Pearce Healthcare Quality Quest Clinical audit tool to promote quality for better health services Contents 1 Introduction 1 1.1 Who

More information

Data platforms to support research, evaluation & practice. David V Ford Professor of Health Informatics School of Medicine, Swansea University

Data platforms to support research, evaluation & practice. David V Ford Professor of Health Informatics School of Medicine, Swansea University Data platforms to support research, evaluation & practice David V Ford Professor of Health Informatics School of Medicine, Swansea University Outline 1. Swift overview of SAIL Databank as used in Wales

More information

IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS

IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS 29 OCTOBER 2015 DR. DIRK J. EVERS BACKGROUND TreatmentMAP

More information

INTRODUCTION. Chapter One

INTRODUCTION. Chapter One Chapter One INTRODUCTION Human tissues have been stored for a long time. Some institutions in the United States have archived specimens of human tissues that are more than 100 years old. Historically,

More information

Big Data and CancerLinQ

Big Data and CancerLinQ Big Data and CancerLinQ Peter Paul Yu, MD, FACP, FASCO Immediate-Past President American Society of Clinical Oncology TACOS Phoenix, Arizona November 13, 2015 Disruptive Change in Oncology driving change

More information

Delivering the power of the world s most successful genomics platform

Delivering the power of the world s most successful genomics platform Delivering the power of the world s most successful genomics platform NextCODE Health is bringing the full power of the world s largest and most successful genomics platform to everyday clinical care NextCODE

More information

Introduction to Pathology and Diagnostic Medicine

Introduction to Pathology and Diagnostic Medicine Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?

More information

Ethical and Public Health Implications of Genomic and Personalised Medicine. Dr Ingrid Slade

Ethical and Public Health Implications of Genomic and Personalised Medicine. Dr Ingrid Slade Ethical and Public Health Implications of Genomic and Personalised Medicine Dr Ingrid Slade Ethical and Public Health Implications of Genomic and Personalised Medicine What is personalised medicine and

More information

Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation

Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements ACKNOWLEDGEMENTS The authors

More information

Clinical and research data integration: the i2b2 FSM experience

Clinical and research data integration: the i2b2 FSM experience Clinical and research data integration: the i2b2 FSM experience Laboratory of Biomedical Informatics for Clinical Research Fondazione Salvatore Maugeri - FSM - Hospital, Pavia, italy Laboratory of Biomedical

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Environmental Health Science. Brian S. Schwartz, MD, MS

Environmental Health Science. Brian S. Schwartz, MD, MS Environmental Health Science Data Streams Health Data Brian S. Schwartz, MD, MS January 10, 2013 When is a data stream not a data stream? When it is health data. EHR data = PHI of health system Data stream

More information

Big Data and Oncology Care Quality Improvement in the United States

Big Data and Oncology Care Quality Improvement in the United States Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.

More information

The Danish Biobank System a unique resource for biomedical research and development

The Danish Biobank System a unique resource for biomedical research and development The Danish Biobank System a unique resource for biomedical research and development Professor Stephen Hamilton-Dutoit Chair of Pathology, Aarhus University Denmark Denmark a great little country for biobank

More information

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid

More information

4.11 Healthcare Technology Co-operatives Version 4 (July 2015)

4.11 Healthcare Technology Co-operatives Version 4 (July 2015) HEALTHCARE TECHNOLOGY CO-OPERATIVES Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out

More information

Mapping the UK Precision Medicine Landscape

Mapping the UK Precision Medicine Landscape Mapping the UK Precision Medicine Landscape What is precision medicine? Precision medicine refines our understanding of disease prediction and risk, onset and progression in patients, informing better

More information

The role of PARP inhibitors in high grade serous ovarian cancers

The role of PARP inhibitors in high grade serous ovarian cancers The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair

More information

Taking Part in Research at University Hospitals Birmingham

Taking Part in Research at University Hospitals Birmingham University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121

More information

Opportunities for African Participation in H2020. Research and Innovation Work Programme 2016-2017

Opportunities for African Participation in H2020. Research and Innovation Work Programme 2016-2017 Opportunities for African Participation in H2020 Research and Innovation Work Programme 2016-2017 caast-net-plus.org CAAST-Net Plus is funded by the European Union s Seventh Framework Programme for Research

More information

Specialist Palliative Care National Clinical Data Collection Pilot

Specialist Palliative Care National Clinical Data Collection Pilot Specialist Palliative Care National Clinical Data Collection Pilot Presenter: Katie Lindsey. Public Health England The vision...better data from specialist palliative care to: Support care delivery- adding

More information

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management A Gene Expression Test to Predict Prostate Cancer Aggressiveness Use Prolaris as a guide in your medical and surgical management What is Prolaris? A direct molecular measure of prostate cancer tumor biology

More information

Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12

Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12 Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12 NHS Commissioning Board Commissioning Policy: Defining the Boundaries between NHS and

More information

Coversheet for Network Site Specific Group Agreed Documentation

Coversheet for Network Site Specific Group Agreed Documentation Coversheet for Network Site Specific Group Agreed Documentation Document Title Clinical Management Protocol Children s Hepatic Tumours Document Date July 2010 Document Purpose Authors Modalities of treatment

More information

All. Report BREAST CANCER. A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006

All. Report BREAST CANCER. A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006 All BREAST CANCER Report A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006 West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements

More information

Data-driven Medicine in the Age of Genomics Overcoming the Challenge With Advanced Molecular Analytics

Data-driven Medicine in the Age of Genomics Overcoming the Challenge With Advanced Molecular Analytics Data-driven Medicine in the Age of Genomics Overcoming the Challenge With Advanced Molecular Analytics David A Dworaczyk, PhD Life and Health Sciences Strategic Development 11 December, 2014 Safe Harbor

More information

Building a Collaborative Informatics Platform for Translational Research: Prof. Yike Guo Department of Computing Imperial College London

Building a Collaborative Informatics Platform for Translational Research: Prof. Yike Guo Department of Computing Imperial College London Building a Collaborative Informatics Platform for Translational Research: An IMI Project Experience Prof. Yike Guo Department of Computing Imperial College London Living in the Era of BIG Big Data : Massive

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

INVITATION TO TENDER STAGE ONE: PRE-QUALIFICATION NHS GENOMIC MEDICINE CENTRE SELECTION

INVITATION TO TENDER STAGE ONE: PRE-QUALIFICATION NHS GENOMIC MEDICINE CENTRE SELECTION INVITATION TO TENDER STAGE ONE: PRE-QUALIFICATION NHS GENOMIC MEDICINE CENTRE SELECTION NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information Nursing Policy Commissioning

More information

Click to edit Master title style

Click to edit Master title style O ral Cancer - so much research, Click to edit Master title style so little progress-why? Click to edit Master text styles Second Level Christopher Squier Third Level Department of O ral Pathology Fourth

More information

Systems Biology: A Personal View XV. Network Medicine. Sitabhra Sinha IMSc Chennai

Systems Biology: A Personal View XV. Network Medicine. Sitabhra Sinha IMSc Chennai Systems Biology: A Personal View XV. Network Medicine Sitabhra Sinha IMSc Chennai Diseases, Genes and Networks http://learn.genetics.utah.edu/ Now that we have the ability to sequence entire genomes, can

More information

CORPORATE OVERVIEW. Big Data. Shared. Simply. Securely.

CORPORATE OVERVIEW. Big Data. Shared. Simply. Securely. CORPORATE OVERVIEW Big Data. Shared. Simply. Securely. INTRODUCING PHEMI SYSTEMS PHEMI unlocks the power of your data with out-of-the-box privacy, sharing, and governance PHEMI Systems brings advanced

More information

The Research Capability Programme. Peter Knight, Group Programme Director

The Research Capability Programme. Peter Knight, Group Programme Director The Research Capability Programme Peter Knight, Group Programme Director 11/03/2010 RESEARCH FOR PATIENT BENEFIT WORKING PARTY FINAL REPORT For us, science and research constitute a front-line service,

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

Diagnostics guidance Published: 25 September 2013 nice.org.uk/guidance/dg10. NICE All rights reserved.

Diagnostics guidance Published: 25 September 2013 nice.org.uk/guidance/dg10. NICE All rights reserved. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostratat Diagnostics

More information